Avidian Wealth Enterprises’s BioCryst Pharmaceuticals BCRX Stock Holding History

Avidian Wealth Enterprises’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31,000	Closed	-$504K	–	455
2022 Q1	$504K	Hold	31,000	–	–	0.03%	302
2021 Q4	$429K	Hold	31,000	–	–	0.03%	330
2021 Q3	$445K	Hold	31,000	–	–	0.03%	232
2021 Q2	$490K	Buy	31,000 +1,000	+3%	+$13.6K	0.04%	226
2021 Q1	$305K	Buy	+30,000	New	+$309K	0.03%	283

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Avidian Wealth Enterprises's BCRX Position: Q2 2022 in Review

Avidian Wealth Enterprises sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 31,000 shares — an estimated $504K sold.

Avidian Wealth Enterprises first reported a position in BCRX in Q1 2021 and held it in 5 quarters. The position peaked at $504K in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

Avidian Wealth Enterprises reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Avidian Wealth Enterprises sold 31,000 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $504K.
Avidian Wealth Enterprises first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Avidian Wealth Enterprises's BioCryst Pharmaceuticals position peaked at $504K in Q1 2022.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Avidian Wealth Enterprises's 13F filing for Q2 2022, filed 29 Jul 2022.